In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
A landmark regulatory update aims to speed approvals, reduce bureaucracy, and strengthen the UK’s position as a global …
The Phase III ENGOT-OV44/First trial delivers a milestone in ovarian cancer research, suggesting immunotherapy could redefine standard of …
December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
On December 19, the clinical research world turns its attention to psychedelic medicine, with new data, global trial …
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …